Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Biopharma Insights


Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

   by Andrii Buvailo    2749
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is to become a leading international organization for advancing artificial intelligence innovations in Drug Discovery, Clinical Research, Diagnostics, Precision Medicine and other key areas of pharmaceutical research and healthcare. The newly formed alliance will be a voice of the industry in matters of education, lobbying for policies and regulations, facilitating investment, and promoting AI-innovations among top drug makers and healthcare institutions.

The Future Of Drug Development in China

   by Dr. Gerald J. Yakatan    4801
The Future Of Drug Development in China

China has been becoming a research powerhouse in many fields of science, but it still is a minor player when it comes to pharmaceuticals. However, recent developments suggest that China’s role in pharmaceutical research may change in the near future.

Will Biologics Surpass Small Molecules In The Pharma Race?

   by Andrii Buvailo    19752
Will Biologics Surpass Small Molecules In The Pharma Race?

The first biologics drug, humanized insulin (5.8 kDa), became available in 1982 following the advent of biotechnology, and it marked a new era in pharmaceutical industry. Modern advances in biotechnology permit large-scale syntheses of biologics in a more or less cost-effective manner. Having once started with large peptides and recombinant proteins, biologics nowadays include a wide range of other entities, such as antibodies, monoclonal antibodies, and more recently, nanobodies and related objects, soluble receptors, recombinant DNA, antibody-drug conjugates (ADCs), fusion proteins, immunotherapeutics, and synthetic vaccines.  

The “Why”, “How” and “When” of AI in Pharmaceutical Innovation

   by Andrii Buvailo    3304
The “Why”, “How” and “When” of AI in Pharmaceutical Innovation

(Edited version of this post originally appeared in Forbes)

“It is not the strongest of the species that survives, nor the most intelligent, but the one most adaptable to change” -- Leon C. Megginson

Last year brought about new hope and even more hype around the idea of applying artificial intelligence (AI) for “revolutionizing” drug discovery research -- via machines being able to “learn” chemistry and biology from vast amounts of experimental data to propose potent drug candidates, accurately predict their properties and possible toxicity risks. It is supposed to dramatically minimize failures in clinical trials -- saving R&D budgets, time, and most importantly, lives of patients.

Top 7 Trends In Pharmaceutical Research In 2018

   by Andrii Buvailo, Alfred Ajami    40394
Top 7 Trends In Pharmaceutical Research In 2018

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead of the game.

External innovations come in different forms and originate in different places -- from university labs, to privately held venture capital-backed startups and contract research organizations (CROs). Let’s get to reviewing some of the most influential research trends which will be “hot” in 2018 and beyond, and summarize some of the key players driving innovations.